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Summary: This systematic review of RCTs and robust quasi-experimental and 
epidemiological studies, suggests likely benefits for people with asthma of vaccination 
against influenza infection, respiratory illness, asthma attacks and other influenza-related 
asthma complications including asthma related emergency department visits and 
hospitalizations.
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Abstract  
There is uncertainty about the effectiveness of influenza vaccination in people with asthma 
and its impact on asthma outcomes, which may contribute to the sub-optimal vaccination 
rates in people with asthma. This systematic review and meta-analysis involved searching 12 
international databases for randomized controlled trials (RCTs) and high quality quasi-
experimental and epidemiological studies (1970 to 2016). The risk of bias was low for three 
included RCTs. The quality of three included observational studies was moderate. The 
quality of evidence was very low for all study outcomes. Pooled vaccine effectiveness in 
1,825 people with asthma from two test-negative design case-control studies was 45% (95% 
CI 31 to 56) for laboratory-confirmed influenza. Pooled efficacy of live vaccines in reducing 
influenza was 81% (95% CI 33 to 94). Live vaccine reduced febrile illness by 72% (95% CI 
20 to 90). Influenza vaccine prevented 59-78% of asthma attacks leading to emergency visits 
and/or hospitalizations. For people with asthma influenza vaccination may be effective in 
both reducing influenza infection and asthma attacks.  
 
 
Abbreviations  
ACIP: Advisory Committee on Immunization Practices; CI: Confidence interval; ED: Emergency Department; 
EPHPP: Effective Public Health Practice Project; GRADE: Grading of Recommendations Assessment, 
Development and Evaluation; ILI: Influenza-like illness; LAIV: Live attenuated influenza vaccine; OR: Odds 
ratio; PROSPERO: Prospective register of systematic reviews; RCT: Randomized controlled trial; RR: Risk 
ratio; RT-PCR: Real time – polymerase chain reaction; S.D: Standard deviation; TND: Test negative design; 
US: United States; VE: Vaccine efficacy or effectiveness; WHO: World Health Organization;  
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Introduction 
Influenza is an acute respiratory illness caused by infection with the influenza virus, which 
can be severe and, particularly in high-risk groups, result in considerable morbidity and, in 
some cases, death [1]. Worldwide, influenza causes an estimated five million cases of severe 
illness and half a million deaths each year, costing the United States (US) an estimated 
US$87 billion per annum [2, 3]. 
 
In people with asthma, chronic airway inflammation and 
type-2 immune responses is thought to impair antiviral immunity in the respiratory tract,[4] 
resulting in susceptibility to severe influenza illness and associated bacterial infection. 
Mechanisms of increased susceptibility to influenza in asthma include weaker innate immune 
and T-helper 1 cell responses and a deficient interferon alpha response of plasmacytoid 
dendritic cells to influenza [5]. Furthermore, influenza infections can lead to severe asthma 
attacks often requiring hospitalization [6]. 
 
Annual immunization with influenza vaccine is currently recommended by the World Health 
Organization (WHO) and national immunization technical advisory groups in the US and a 
number of European and other high-income countries [3, 7].
 
The uptake in people with at-risk 
conditions – including asthma – is however well below the target of 75% (e.g. 40% in the US 
2015-16) [8-10]. The reasons for this lack of coverage are complex and multifactorial, but 
include a lack of confidence in patients and health care providers in the effectiveness and 
safety of vaccines [11]. Important in this respect is the hypothesis that the defective mucosal 
and systemic immunity in asthma may reduce protection provided by influenza vaccines [12, 
13]. There may be some grounds to this concern in the context of asthma as a recent 
Cochrane systematic review [14] investigating the effectiveness of influenza vaccination in 
those with asthma was inconclusive regarding the efficacy of influenza vaccines. Also of 
concern is that the safety of live influenza vaccines in infants with wheezing disorders/asthma 
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has not yet been conclusively established [14].
 
Given that placebo randomized controlled 
trials (RCT)s of influenza vaccination are no longer undertaken in people with asthma (the 
last placebo RCT was carried out in 2001 with none planned),[15] there is the need, in 
addition to RCTs, to also consider evidence from other study designs [16]. We therefore 
carried out a systematic review and meta-analysis of RCTs and robust quasi-experimental and 
epidemiological studies to evaluate the efficacy, effectiveness and safety of influenza 
vaccination in people with asthma. 
 
Methods 
Selection criteria and search strategy  
Our methods have been described in detail in our published protocol [17] (PROSPERO 
registration: CRD42016037219). We searched the published literature (January 1970 to 
January 2016) for studies investigating the effectiveness of influenza vaccination in people 
with asthma. Our start date was chosen as the evidence on this subject began to accrue 
following publication of the paper by Bell et al. in [18] 1978 [19, 20]. See Supplementary 
Appendix I for search strategies.  
 
Risk of bias assessment in individual studies  
Two reviewers (EV and KF) independently assessed the risk of bias, and disagreements were 
resolved through discussion or by the involvement of a third reviewer (CS). The risk of bias 
of experimental studies was based on the suggested algorithm in the Cochrane 
Collaboration’s tool [21]. Overall low risk of bias was assigned to a study with low risk of 
bias for all six domains, overall unclear risk was assigned to a study with unclear risk of bias 
for one or more domains, and overall high risk of bias was assigned to a study with high risk 
of bias for one or more domains.  
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The Quality Assessment Tool for Quantitative Studies Dictionary developed by the Effective 
Public Health Practice Project (EPHPP) was used for the evaluation of observational studies 
and non-randomized controlled studies [22]. The overall quality was rated as strong in the 
absence of weak ratings in each of the six components, moderate overall rating in the 
presence of one weak rating, and weak overall rating in the presence of two or more weak 
ratings.  
 
Data analysis 
Separate meta-analyses were performed for clinically and methodologically comparable 
experimental and observational studies in order to estimate the incidence or frequency of 
influenza infection (laboratory confirmed) and febrile illness. Random-effects models were 
used to summarize the findings depending on the degree of clinical heterogeneity of the 
studies. For dichotomous outcomes, the treatment effect was estimated using a risk ratio (RR) 
with 95% confidence intervals (CI) or odds ratio (OR) with 95% CIs. Vaccine 
efficacy/effectiveness (VE) is usually reported as a percentage e.g. (1-OR)*100. Safety data 
from cross-over trials could not be pooled together due to lack of adequate data regarding the 
two cross-over periods. Statistical heterogeneity was assessed using the standard χ2 test and I2 
statistic, which describes the proportion of dispersion across studies due to true heterogeneity 
rather than to a sampling error (0-100% heterogeneity). We contacted authors of included 
studies that had missing data. All statistical analyses were undertaken using RStudio version 
0.99.893 [23].   
 
‘Confidence intervals (for figures 1-5 in Supplementary Appendix II) were produced using 
the generic inverse variance method for meta-analysis. We provided pooled estimates for 
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each VE outcome combining all study designs (regardless of their clinical or methodological 
heterogeneity). Due to studies’ asymmetric 95% CIs, pooled treatment effects and their 95% 
CIs were provided using the log relative estimates and standard errors as input.’ 
Results 
Selection of studies and study characteristics  
Our initial research identified 20,396 unduplicated records. After screening titles and 
abstracts, 318 potentially eligible studies were selected for full review. Thirty-two studies 
eligible for inclusion were identified through database searches and a further three studies 
through reference screening. We therefore included 35 studies enrolling 142,519 patients 
with asthma in the qualitative synthesis and four studies in the meta-analyses (Figure 1). A 
brief summary of vaccine types per each endpoint is provided in Table 1. Full citations for 
these 35 articles [A1–A35] are provided in Supplementary Appendix II, along with detailed 
study characteristics and methodological critiques (Tables S1-8). 
 
Risk of bias assessment in individual studies 
The overall risk of bias was high in five RCTs, unclear in 12 RCTs and low in three RCTs 
(Figure 2). The overall quality of 12 studies (six non-RCTs and six cohort studies) was rated 
as “weak”. In two case-control studies and in one cohort study, the overall quality was rated 
as “moderate” (Figure 3) (Tables S2-5).  
 
Overall quality of evidence 
The body of evidence regarding influenza VE and safety regarding primary and secondary 
outcomes was rated using the GRADE approach as being of very low quality due to 
inconsistency, indirectness, and imprecision across studies. In addition, the strength of 
 8 
 
evidence for the protective effects of vaccination against pulmonary function and school or 
work absenteeism was rated as very low since the evidence was based on single studies. 
Thus, the consistency, directness, and precision of the pooled overall estimation could not be 
assessed. Similarly, the evidence of safety of influenza vaccination against influenza 
infection and respiratory tract illness was assigned as very low as it was provided by single 
studies (Table S6).  
 
Vaccine efficacy and effectiveness against influenza infection  
Nosocomial outbreaks of A (H1N1) and B subtypes were observed during two consecutive 
years (1988-89 and 1989-90) among 84 children with asthma [A12, A20]. Protection 
provided by LAIV in these children against laboratory confirmed influenza was found in two 
small RCTs (pooled VE 81%; 95% CI: 33 to 94; Figure 4). A large multicenter RCT 
evaluated the efficacy of the live vaccine compared to the inactivated vaccine against 
community-acquired culture-confirmed influenza illness in children (aged 6-17 years) [A6]. 
LAIV efficacy was significantly higher than the inactivated influenza vaccine. LAIV efficacy 
against influenza subtypes antigenically similar to those included in the vaccine was 35% 
(95% CI: 4 to 56).  
 
A meta-analysis was undertaken of two TND studies performed in the US during the seasons 
2011-13 [A31, A32].
 
In 2011/12, the influenza vaccine in the US was well matched and 
influenza A H3N2 predominated with A H1N1 and both influenza B (Victoria and 
Yamagata) also circulating [24]. In 2012/13, H3N2 again predominated with a late season 
predominance of influenza B [25]. The influenza VE for people with asthma ranged was 38% 
(95% CI: 0 to 63·0) in 2011/12 and 46% (95% CI: 32 to 58) in 2012/13. Once these results 
were pooled, we found an overall VE of 45% (95% CI: 31 to 56; Figure 5) in preventing RT-
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PCR laboratory confirmed influenza in 1,825 individuals with asthma (aged >6 months) 
[A31, A32].
 
 
One prospective cohort study assessed the effectiveness of the influenza vaccine in 
preventing influenza in 338 children (2005/6 season). There were no laboratory confirmed 
influenza infection cases in the vaccinated group, while eight (4·4%) unvaccinated children 
had an infection [A33]. In a non-RCT, efficacy of inactivated vaccine was 42% (95% CI: 21 
to 57) against influenza infection (diagnosed by virus isolation or HI antibody titre increase) 
in 137 children (aged 2-14 years) [A26].  
Vaccine efficacy and effectiveness against asthma attacks and other clinical outcomes  
Protective effects of vaccination against asthma exacerbation were also observed in four 
studies [A7, A28, A29, A35]. One RCT [A7] found that influenza vaccine protected against 
the incidence, frequency and duration of asthma attacks in 201 children (aged 1-15 years). 
Acute asthma attacks were lower in the vaccinated group (39/79) compared to the 
unvaccinated group (82/122) (RR 0.73; 95% CI: 0.57 to 0.95).   
 
VE against asthma attacks was also studied in three observational cohort studies [A28, A29, 
A35]. In the first study, inactivated influenza vaccine provided higher protection against 
asthma attacks (defined as wheezing episodes) (mean + S.D.: 1·6 + 1.6) compared to the 
unimmunized group (mean + S.D.: 6·2 + 3.9) (p<0.001) [A28]. The second study found a 
reduction in attacks after controlling for asthma severity and other confounders. Protective 
incidence rate ratios were observed for the 1994/5 season (0·59; 95% CI: 0·43 to 0·81), and 
the 1995/6 season (0·65; 95% CI: 0·52 to 0·80), but not for the 1993-4 season (0·78; 95% CI: 
0·55 to 1·10) [A29]. In the third study, the rate of asthma attacks was significantly (p=0.037) 
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lower in the vaccine group (mean + S.D.: 0·14 + 0·4) compared to control group (mean + 
S.D.: 0·35 + 0·61) during the 2002/3 season, but not in the 2001/2 season [A35].  
  
Six studies assessed VE in preventing hospitalizations from asthma attacks or respiratory 
infections [A2, A7, A21, A26-A28]. A RCT assessed the duration of hospitalization for 
influenza-like-illness (ILI) accompanied by asthma, ILI and asthma alone in 93 children 
(aged 6-16). The length of hospitalization for ILI alone (p<0·01) and ILI accompanied by 
asthma (p<0·05) was significantly lower in the bivalent inactivated vaccine group compared 
to the unvaccinated group [A2]. In a cohort study, the number of hospitalizations was 0·2 + 
0·6 (mean + S.D.) among the inactivated vaccine recipients and 1·3 + 1·5 (mean + S.D.) 
among controls (p<0.001) [A28].  
 
Two studies [A6, A27] assessed the protective effects of vaccination against asthma or 
respiratory illness consultations. A retrospective cohort study reported higher visits to a 
pediatric clinic among vaccine recipients (2.14) than in the unvaccinated ones (0.71; OR: 2·9; 
95% CI: 2·0 to 4·1) [A27]. 
 
VE against respiratory illness was found in four studies [A26, A28, A33, A34]. Pooled 
estimates regarding live attenuated VE against febrile illness were estimated from two RCTs 
[A12, A20]. Pooled VE of 72% (95% CI: 20 to 90; Figure 6) was observed against febrile 
illness during two nosocomial outbreaks with A (H1N1) and B subtypes [A12, A20]. In 
another trial, clinical efficacy of inactivated subunit vaccine against febrile influenza illness 
was 49% (95% CI: 24 to 66) in 137 children (aged 2-14 years) (p<0.01). A higher vaccine 
efficacy (74%) was observed in children < seven years old (p<0.01) [A26]. Three cohort 
studies reported protective effects of vaccination against respiratory illness. In the first study, 
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the number of respiratory tract illnesses were significantly lower (mean + S.D.: 2·2 + 2·1) in 
the inactivated vaccine recipients compared to the unvaccinated group (mean + S.D.: 6·9 + 
3·9) (p<0.001) [A28]. The second study found that 0·6% of vaccine recipients had a 
respiratory syncytial virus infection compared to 2·5% of controls. In addition, protective 
effects of the vaccine were also observed against other respiratory infections (RR: 0·61; 95% 
CI: 0·29 to 0·95) and bronchiolitis (RR: 0·47; 95% CI: 0·26 to 0·84) [A33]. In the last study, 
the effectiveness of the inactivated subunit vaccine was 56% (95% CI: 18 to 76) against acute 
respiratory disease (defined as ILI, bronchitis, bronchiolitis, asthma exacerbation or otitis 
media) during the 1996-7 season. In particular, higher VE of 77% (95% CI: 35 to 92) was 
found in younger children < six years old [A34].
 
  
 
The VE in preventing asthma-related emergency department (ED) visits was evaluated in 
three studies [A7, A27, A28]. A cohort study observed lower ED visits for asthma 
exacerbations among inactivated vaccine recipients (mean + S.D.: 0·4 + 0·9) than the 
unvaccinated group (mean + S.D.: 2·2 + 2·6) (p<0.001) [A28]. In contrast, another cohort 
study of vaccinated children had more ED visits for asthma or pneumonia (OR 2·0; 95% CI: 
1·2 to 3·1) [A27].
  
 
 
The protective effects against increased use of asthma medication were also reported in two 
studies [A7, A28]. In a RCT, the frequency of bronchodilator use was lower in the vaccinated 
group (35/79) compared to unvaccinated group (77/122; VE: 50%; 95% CI: 0.34 to 0.64) 
[A7].
 
A cohort study reported significantly (p<0.001) higher number of bronchodilator 
administrations in the unvaccinated group (mean + S.D.: 6·2 + 3·9) than the inactivated 
vaccine group (mean + S.D.: 1·6 + 1·6). Similarly, prednisolone administrations were 
significantly (p<0.001) higher in the unvaccinated group (mean + S.D.: 1·1 + 1·2) compared 
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to vaccinated group (mean + S.D.: 0·1 + 0·3) [A28]. No improvements in pulmonary function 
and reduction in work/school absenteeism were found from influenza vaccine [A6, A21]. 
Safety 
There was no increased risk of serious local or systemic adverse reactions, or vaccine-related 
asthma exacerbations or symptoms (e.g. wheeze) or respiratory illnesses [A1, A4-20, A22, 
A22-25, A30]. One trial comparing live to inactivated vaccine found a significant increase in 
wheezing symptoms in the inactivated group [A6]. In two [A2, A15] of 16 studies pulmonary 
function deterioration was found following vaccination, although these were not 
accompanied by asthma symptoms, increased medication or health-care utilization. We found 
four non-RCTs [A22-A25] and one observational study [A30] (not included in the Cates 
review [14]). These found that influenza vaccine led to no increase in post-vaccine asthma 
attack or symptoms when compared to placebo (for non-RCT studies) or no vaccine 
(observational studies) (Table S7).  
 
Discussion  
Our findings indicate that influenza vaccination prevents influenza and other clinically 
important health outcomes in people with asthma. Pooled estimates from observational TND 
studies suggest that influenza vaccination is beneficial against laboratory-confirmed influenza 
(VEs ranging from 38-46%, with a pooled estimate of 45%) [A31, A32]. Influenza 
vaccination reduced asthma exacerbations, healthcare use, respiratory illness and medications 
for asthma [A2, A7, A12, A20, A26, A28, A29, A33, A35]. However, much of this evidence 
comes from observational studies and therefore bias and residual confounding are alternative 
possible explanations. For each outcome also, the quality of the body of evidence (across all 
included studies using GRADE) was very low. 
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There are several reasons why there is a need to consider evidence from robust quasi-
experimental and observational studies. A Cochrane review of RCTs on this subject, which 
found inconclusive evidence to support influenza vaccination in those with asthma,[14] 
whilst well conducted, was however of limited value to decision makers, clinicians or 
patients. This is because there have been no relevant placebo RCTs over the last 15 years and 
none are in progress or planned as it has been considered unethical to withhold vaccination, 
particularly from those most at risk of severe influenza illness. Furthermore, observational 
TND studies are used to help inform national advisory bodies on their influenza vaccination 
programs. For instance, the US Advisory Committee on Immunization Practices (ACIP) did 
not recommend the use of LAIV for the 2016/17 season due to evidence of no effectiveness 
(3%) of LAIV from US based TND studies [7]. Amongst children with a history of asthma or 
wheezing however superior efficacy of LAIV was found compared to trivalent inactivated 
influenza vaccine [26]. Therefore, further research to establish the effectiveness of LAIV 
amongst children with asthma using observational study data is required [27].  
Strengths and limitations  
Most studies differed by recruitment methods, vaccine ascertainment methods, type of 
vaccines and outcome definitions (in some cases outcomes were not described). Particularly, 
the definition and evaluation of asthma exacerbations is an important point of variability 
across studies. An additional file shows further characteristics of included studies (Table S8). 
Most studies (experimental and observational) also recruited children or adults less than 65 
years old. Thus, only a few studies have assessed influenza vaccination in older people with 
asthma.  
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In three RCTs, the low sensitivity of viral culture tests to confirm influenza infection may 
have affected the accuracy of the results [A12, A20, A26]. Furthermore in three studies, 
residual immunity from previous vaccination or influenza exposure from previous seasons 
may have affected VE estimates [A31, A32, A34]. 
 
With the small number of studies included in each meta-analysis, publication bias could not 
be adequately assessed. Planned subgroup and sensitivity analysis (e.g. VE against influenza 
B and influenza A sub-types) could not be carried out due to lack of data from the included 
studies [17]. Also, more in-depth analyses, which include the number, nature and antigenic 
distance specified by virus mutations across sequential circulating variants and vaccine 
components and the role of prior vaccination are required [28]. This will require larger TND 
studies with pooling of data across regions and countries. We did not found new substantive 
evidence for LAIV safety, beyond those studies included in the Cates’ review [14]. 
 
Conclusions  
Public health initiatives are required to improve the current low vaccine uptake in people with 
asthma [10]. Evidence from clinical trials and observational studies suggests that the 
influenza vaccine is safe and that it likely benefits people with asthma against influenza 
infection, respiratory illness, asthma attacks and other influenza-related asthma complications 
including asthma related ED visits and hospitalizations.   
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Figure 1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
diagram. 
Figure 2: Risk of bias summary: review authors’ judgments about each risk of bias item for 
each RCT. *this rating was based on the Cochrane guideline 
Figure 3: Quality assessment of the non-RCTs and observational studies using the EPHPP 
quality assessment tool.  
Figure 4: Live attenuated influenza vaccine versus no vaccine against influenza infection 
(RCTs) 
Figure 5: Seasonal influenza vaccine versus no vaccine against laboratory confirmed (RT-
PCR) influenza infection (test-negative design studies)  
Figure 6: Live attenuated influenza vaccine versus no vaccine against febrile illness (RCTs)  
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Publications (No.) per vaccine typea 
Publications (No.)  per outcomea Inactivated Live Both Not specified  
*Influenza  1 2 1 3 
(7 publications) Sugaya 1994 [A26] 
 
Miyazaki 1993 [A12] 
Tanaka 1993 [A20] 
 
Fleming 2006 [A6] 
 
McLean 2015 [A31] 
Ohmit 2014 [A32] 
Otero 2009 [A33] 
*Asthma exacerbation 4   3 
(7 publications) Bueving 2004 [A3] 
Abadoglu 2004 [A21] 
Sugaya 1994 [A26] 
Jaiwong 2015 [A28] 
  Gharagozlou 2006 [A7] 
Kramarz 2001 [A29] 
Watanabe 2005 [A35] 
Hospitalization  4   2 
(6 publications)  Bell 1978 [A2] 
Abadoglu 2004 [A21] 
Sugaya 1994 [A26] 
Jaiwong 2015 [A28] 
  Gharagozlou 2006 [A7] 
Christy 2004 [A27] 
 
Consultations   1 1 
(2 publications)    Fleming 2006 [A6] 
 
Christy 2004 [27] 
Emergency visits  1   2 
(3 publications) Jaiwong 2015 [A28]   Gharagozlou 2006 [A7] 
Christy 2004 [A27] 
 
Respiratory illness  5 2  1 
(8 publications) Bueving 2004 [A3] 
Abadoglu 2004 [A21] 
Sugaya 1994 [A26] 
Jaiwong 2015 [A28] 
Smits 2002 [A34] 
Miyazaki 1993 [A12] 
Tanaka 1993 [A20] 
 
 Jaiwong 2015 [A28] 
 
Asthma medication 1   1 
(2 publications) Jaiwong 2015 [A28]   Gharagozlou 2006 [A7] 
 
Pulmonary function  1    
(1 publication) Abadoglu 2004 [A21]    
School/work absence    1  
(1 publication)   Fleming 2006 [A6]  
Safety 17 4 1 2 
(24 publications)  Bell 1978 [A2] 
Bueving 2004 [A4] 
Castro 2001 [A5] 
Govaert 1993 [A8] 
Hahn 1980 [A9] 
Kmiecik 2007 [A10] 
Miller 2003 [A11] 
Nicholson 1998 [A13] 
Ortwein 1987 [A14] 
Pedroza 2009 [A15] 
Reid 1998 [A17] 
Sener 1999 [A18] 
Stenius 1986 [A19] 
Campbell 1984 [A22] 
Chiu 2003 [A23] 
Kava 1987 [A24] 
Kim 2003[A25] 
Atmar 1990 [A1] 
Miyazaki 1993 [A12] 
Redding 2002 [A16] 
Tanaka 1993 [A20] 
 
 
 
 
 
 
 
Fleming 2006 [A6] 
 
Gharagoszlou 2006 [A7] 
Kramarz 2000 [A30] 
a See Supplementary Appendix II for details 
*Primary outcomes  
 
Table 1. Summary of publications reporting the effectiveness and safety of influenza vaccines  
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